IBM’s Watson to use genomic data to defeat drug-resistant cancers

IBM’s Watson artificial intelligence platform has joined forces with researchers at MIT and Harvard to study how thousands of cancers mutate to become resistant to drug treatments that initially worked to beat back the disease.

By discovering how cancers adapt to overcome drug therapies, researchers at MIT’s and Harvard’s Broad Institute genomics research center hope to develop a new generation of therapies that cancers cannot circumvent.

While a growing number of treatments can hold cancers in check for months or years, most cancers eventually recur, according to the Broad Institute researchers. This is in part because tumors acquire mutations that make them drug resistant.

To read this article in full or to leave a comment, please click here

Computerworld Cloud Computing